2023 Posters

JL1101EH: Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

Presenter: Jessica Cheadle, NP


Saad Z Usmani1, Lionel Karlin2, Lotfi Benboubker3, Hareth Nahi4, Jesús San-Miguel5, Danielle Trancucci6, Keqin Qi7, Tara Stephenson8, Alfredo Perales Puchalt8, Katherine Chastain6, Ajai Chari9

1 Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2 Centre Hospitalier Lyon Sud, France; 3 Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours, France; 4 Karolinska University Hospital at Huddinge, Stockholm, Sweden; 5 University of Navarra, Pamplona, Spain; 6Janssen Research & Development, Raritan, NJ, USA; 7 Janssen Research & Development, Titusville, NJ, USA; 8 Janssen Research & Development, Spring House, PA, USA; 9 Mount Sinai School of Medicine, New York, NY, USA

Track: Encore Poster - Hematologic

Display Label Action
JL1101EH.abstract Download Handout